
EV battery recycling heats up in Korea despite market slump
Industry eyes rebound by 2030 as used batteries pile up, global recycling mandates kick in
Korea's industry giants are stepping up their involvement in the electric vehicle battery recycling sector, signaling expectations that the currently subdued industry will evolve into a critical component of the battery value chain.
LG Energy Solution, Korea's largest battery maker, recently formed joint ventures in Europe and the US — with France's Derichebourg and Toyota Tsusho Co., respectively — marking its first direct steps into battery recycling operations in both regions.
SK Ecoplant, a construction engineering unit of SK Group, is expanding its European facility in the Netherlands to add 25,000 metric tons of annual black mass processing capacity, with completion scheduled for 2025.
Posco-GS Eco Materials, a 51:49 joint venture between Posco Holdings and GS Energy, acquired full control of its battery recycler, Posco HY Clean Metal, by purchasing the 35 percent stake held by China's Huayou Cobalt in April.
'It is late compared to other countries' battery industries, as even Chinese companies such as CATL have their own recycling business,' said Park Cheol-wan, a car engineering professor at Seojeong University.
'Yet it is the right path for Korean companies, as securing a stable supply chain for minerals will become increasingly significant.'
These moves come as the battery recycling sector continues to suffer a deep slump, driven by sluggish EV demand and sharp declines in the prices of key battery minerals such as nickel, lithium and manganese.
International lithium carbonate prices, which were above 450 Chinese yuan ($63) per kilogram in January 2023, have fallen to around 50 yuan. Nickel prices also dropped significantly, from over $31,000 per ton to around $20,000.
As a result, SungEel HiTech, one of only two battery recycling companies listed on Korea's tech-focused Kosdaq, has experienced declines in profitability and free cash flow for two consecutive years.
A joint battery recycling project between SungEel HiTech and SK Innovation, announced in 2022, has been indefinitely delayed, while SK Ecoplant's planned facilities in Gyeongju, North Gyeongsang Province, and Kentucky have also shown no signs of progress for years.
The industry, however, anticipates a significant increase in the number of used EV batteries as they reach the end of their life cycle, which is estimated to be around 10 years. This follows the surge in global EV sales in the 2010s, which surpassed one million units in 2015.
With the continued growth of EV adoption, the battery recycling market — valued at $8 billion in 2022 — is projected to expand to as much as $53.57 billion by 2030, according to SNE Research.
Experts say that entering the battery recycling business is increasingly becoming essential for staying competitive in the battery industry, as global policy trends push for recycled minerals to be a core component of battery supply chains.
The European Union requires all EV batteries placed within the region to meet minimum recycled metal content thresholds by 2031: 16 percent for cobalt, 85 percent for lead, 6 percent for lithium and 6 percent for nickel. These requirements will increase by 2036.
Meanwhile, EVs with some key battery components or minerals sourced from foreign entities of concern are excluded from US tax credits under the Inflation Reduction Act, pressuring battery makers to secure materials domestically, often through recycling.
'It is more a matter of broader business strategy than the profitability of recycling itself, whether companies choose to outsource recycled materials or secure them in-house,' Park added.
'(With policy changes in place,) it may become faster to secure used batteries rather than invest in new mines, exploration, refining and metal procurement. To ensure a stable supply of critical minerals, battery makers will be competing as if at war.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 hours ago
- Korea Herald
Kospi closes above 3,020 for first time in 3 1/2 years
Postelection optimism fuels sharp rally, lifting hopes of a market renaissance The Kospi did not just return — it roared back. On Friday, South Korea's benchmark index surged past the long-awaited 3,000 mark and kept climbing, closing at 3,021.84, up 1.48 percent from the previous session. It was the first time the Kospi ended above 3,020 since Dec. 28, 2021. The rally seemed modest at the start, with the index opening just 0.29 percent higher at 2,986.52. Retail investors led early gains with net buying, while foreigners and institutions sold into strength, keeping the benchmark tightly anchored below the key level. That restraint vanished once the Kospi cracked 3,000 around 10:45 a.m. Momentum took over, lifting the index past 3,010 by 11:20 a.m. The market stayed buoyant throughout the afternoon, hovering near 3,010, before accelerating again in the final minutes of trading. The Kospi hit an intraday peak of 3,022.06 just before the close, settling near the high of the day. It was a historic session: Not only did the Kospi reclaim the 3,000 level for the first time since January 2022, but total market capitalization hit a record 2,472 trillion won. According to the Korea Exchange, the Kospi first crossed the 3,000 mark on Jan. 7, 2021, peaking at 3,305 in July that year. But post-COVID-19 momentum faded amid a global slowdown and recession fears, pushing the index into a prolonged slump. For much of the past year, it remained trapped in a narrow range between 2,200 and 2,800. Gains were broad-based, with most of the Kospi's top market heavyweights finishing higher. SK hynix and LG Energy Solution each rose more than 4 percent, while Naver surged nearly 7 percent. Hyundai Motor climbed 1.5 percent and Samsung Biologics added 1.7 percent. The tech-heavy Kosdaq also posted solid gains, rising 1.15 percent to close at 791.5. Institutional and foreign investors bought a combined 84 billion won, offsetting retail selling. Friday's milestone extends a two-week honeymoon rally under President Lee Jae-myung's new administration, reinforcing renewed investor confidence despite external headwinds, including Middle East tensions and lingering tariff risks. The Kospi has staged a near-unbroken rally since June 2, the eve of the general election, logging only one down day on June 13. After crossing the 2,700 mark on Lee's first full day in office, the index has jumped 12 percent, buoyed by expectations for policy reform and pro-growth momentum. 'The Kospi reversed course earlier this year as dip-buying resumed and the Trump administration announced tariff deferrals, with the rally gaining further traction around the presidential election,' the Korea Exchange said. 'The launch of the new administration has eased political uncertainty and lifted sentiment on expectations of market-friendly policies.' Analysts say the market is responding sharply to government signals. 'The Kospi's strength is being driven more by expectations of capital market reform and a valuation rerating than by earnings growth,' said Kang Jin-hyeok, analyst at Shinhan Securities. He added that Friday's rally reflected investor optimism following Thursday's unveiling of a 30.5 trillion won ($22.3 billion) supplementary budget. "This, combined with expectations of one or two additional rate cuts later this year, is fueling hopes for increased liquidity in the market.' Market watchers expect momentum to persist, brushing aside concerns of postelection fatigue. 'If current earnings trends hold, the Kospi could reach 3,100 by year-end,' said Noh Dong-kil, strategist at Shinhan Securities. 'And if rising liquidity drives a further rerating in valuations, the index could climb as high as the 3,400 range.' 'Despite the rally, Kospi's valuation remains at a neutral level," said Lee Soo-jung of Meritz Securities, adding, "With stimulus measures such as the supplementary budget and revisions to the Commercial Act upcoming, there's a strong possibility of an overshoot in the Korean stock market.' Lee anticipated foreigners to remain key drivers. After nearly 10 months of net selling, foreign investors turned net buyers in May, purchasing 1.2 trillion won, followed by an additional 5.3 trillion won in June. They remain net sellers of 8 trillion won year-to-date. Still, caution lingers as external risks and a slowing domestic economy continue to pressure sentiment. 'Despite strong policy momentum and supportive catalysts unique to the Korean market, broader fundamentals and external risks — such as weak earnings prospects, trade tensions and geopolitical instability — should not be overlooked,' said Han Ji-young, strategist at Kiwoom Securities. 'A breakout above 3,100 this year is possible, but navigating volatility will be crucial at those levels.'


Korea Herald
4 hours ago
- Korea Herald
Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology
BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions announces the signing of two strategic Memoranda of Understanding (MOUs) with ZaoDx and Xiong'an MagicBiotech Co., Ltd. These partnerships mark a focused expansion of Gene Solutions' precision oncology efforts into the Chinese market through collaborative technology introduction, research exploration, and localized deployment of its innovative cancer testing platforms. Together, the partnerships reinforce Gene Solutions' long-term commitment to supporting China's healthcare innovation ecosystem with advanced, clinically validated tools for early cancer detection and monitoring. Enabling Early Detection Through Ecosystem Engagement with ZaoDx Gene Solutions and ZaoDx have formed a strategic business alliance to jointly explore the introduction, promotion, and responsible commercialization of advanced early cancer screening technologies in China. This partnership will focus on: CEO of ZaoDx Dr. Chen Zanquan stated: "Cancer is a challenge faced globally, and early detection is crucial for cure. ZAODX is pleased to collaborate with Gene Solutions to advance the conversion and accessibility of innovative cancer screening and diagnosis technologies. I believe our joint efforts will bring tangible benefits to millions of families." "Our collaboration with ZaoDx reflects a shared commitment to bringing global innovation into meaningful local impact," said Jiang Hao, Business Development Manager at Gene Solutions. "By working alongside respected research-driven partners, we can responsibly introduce early detection technology to more patients and providers across the country." Advancing Research Collaboration in Northern China alongside MagicBiotech Gene Solutions and Xiong'an MagicBiotech have signed an MOU to jointly explore the introduction and academic evaluation of next-generation sequencing (NGS)–based oncology technologies across northern China. The collaboration will center on: "Our partnership with MagicBiotech is a cornerstone for advancing precision oncology in China," said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. "By fostering collaborative research and leveraging local expertise, we aim to validate and scale our technologies to meet the region's clinical and scientific needs." Driving Localized Innovation Through Strategic Collaboration These dual partnerships represent a calibrated approach by Gene Solutions to support the introduction and validation of advanced oncology diagnostics in China. Both collaborations are built on mutual strengths—balancing scientific rigor, ethical commercialization, and long-term research-driven engagement. Project-specific initiatives under each MOU will be rolled out progressively in alignment with local regulations and institutional priorities. About ZaoDx ZAODX Early Screening Network is a globally leading platform dedicated to the early detection of diseases, with a core mission to drive the transformation of global healthcare systems from treatment-centric models to a proactive, health-centered paradigm. Guided by the widely recognized principle that "prevention is the most cost-effective and impactful health strategy," ZAODX advocates the global adoption of early screening, early diagnosis, and early treatment — while also drawing inspiration from Traditional Chinese Medicine's wisdom of "treating disease before it occurs." As a truly international and multidisciplinary team, ZAODX brings together key stakeholders across the global healthcare ecosystem — including scientists, entrepreneurs, investors, policymakers, healthcare providers, and public health experts — united by the mission to make health screening accessible and equitable for all. The network has established strategic partnerships with over 1,000 top-tier medical institutions, academic organizations, professional societies, independent laboratories, and healthcare innovators to foster cross-border academic exchange, scientific collaboration, technology translation, industry synergy, and public health education. Committed to global public health goals, ZAODX actively supports initiatives led by the World Health Organization and national health authorities. Through collaborative efforts, ZAODX is building an innovative and inclusive early screening ecosystem — empowering the global fight for earlier prevention, better outcomes, and healthier populations worldwide. About Xiong'An MagicBiotech Xiong'An MagicBiotech is a biotechnology company in Xiongan New Area focusing on "in vitro diagnostic reagents + testing services + artificial intelligence". MagicBiotech is mainly engaged in independent research and development, production and sales of in vitro diagnostic kits for genetic testing. By using multi-omics medical examination data and bioinformatics AI artificial intelligence technology, it provides in vitro diagnostic reagents and medical testing services to medical institutions and patients; in the scientific research and technology service sector, MagicBiotech has always adhered to the concept of innovation-driven, continued to increase R&D investment, and made every effort to build a complete and advanced technology platform system. The system deeply covers cutting-edge fields such as genomics, proteomics, metabolomics, microbiome, and single-cell multi-omics. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
![[Bio USA] Celltrion deepens global ties, unveils R&D vision at Bio USA](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F20%2Fnews-p.v1.20250620.cdcac9ea11d1450b88549214dd282783_T1.jpg&w=3840&q=100)
![[Bio USA] Celltrion deepens global ties, unveils R&D vision at Bio USA](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75)
Korea Herald
5 hours ago
- Korea Herald
[Bio USA] Celltrion deepens global ties, unveils R&D vision at Bio USA
BOSTON — Korean biotech company Celltrion showcased its expanded vision as a next-generation drug developer at Bio USA this week, using the global stage in Boston to deepen ties with international partners and explore cutting-edge biotech collaborations. According to Celltrion on Thursday, the company held more than 150 meetings over the four-day event, engaging in discussions with global pharmaceutical and biotech firms on a wide range of potential collaborations. Over 1,800 visitors stopped by Celltrion's booth during the convention, as announced by the company. Focusing on its core mission of "new drug development" this year, the company concentrated on exploring partnership opportunities to strengthen its pipeline in areas such as antibody-drug conjugates, multispecific antibodies, novel antibody drugs and peptides. The company also held extensive discussions on open innovation initiatives aimed at identifying promising technologies in drug development. Celltrion plans to closely review the meetings from Bio USA to identify potential partners with high growth potential and technical capabilities. In addition, the company said it engaged in wide-ranging talks about expanding its distribution network, receiving collaboration proposals from various companies for drug transportation, storage and other logistical support. Celltrion supplies its biosimilar products through direct sales channels in major global markets. For countries where it relies on indirect sales, the company actively held meetings to strengthen its existing distribution networks. Beyond business meetings, Celltrion also conducted promotional activities throughout the event, such as placing QR-coded brochures throughout its booth to highlight the company's key businesses and major products. Visitors who participated in surveys were offered custom keychains as part of a fun event to drive engagement. 'There was notable interest this year in Celltrion's expansion into the new drug development space,' a Celltrion official said. 'We are committed to securing the best technologies and potential partnerships to advance our pipeline of novel therapeutics. These efforts will reinforce Celltrion's capabilities as it grows into a major global pharmaceutical company.' Celltrion has participated in Bio USA for 16 consecutive years since 2010, continuously seeking global partnerships.